The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,012.00
Bid: 2,000.00
Ask: 2,004.00
Change: 18.00 (0.90%)
Spread: 4.00 (0.20%)
Open: 1,991.00
High: 2,012.00
Low: 1,969.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Nov 2015 15:04

RNS Number : 8763F
Hikma Pharmaceuticals Plc
16 November 2015
 



 

Notification of major interests in shares

 

LONDON, 16 November 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

 

2

Reason for the notification

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached

No

An event changing the breakdown of voting rights

No

Other (please specify): Compliance with the Transparency Directive

No

 

 

3

Full name of the person subject to the notification obligation

FMR LLC

4

Full name of shareholders

See Section 9

5

Date of the Transaction (and date on which the threshold crossed is reached differently)

13th November 2015

6

Date on which the issuer notified

16th November 2015

7

Threshold that is crossed

5%

8

Notified details

See A, B & C below

A. Voting rights attached to shares

Class type of shares (if possible using the ISIN code)

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

Direct

Indirect

Ordinary Shares (0.10 GBP)

GB00B0LCW083

9,966,682

9,966,682

10,038,352

10,038,352

5.03%

 

B. Qualifying Financial instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights that may be acquired if the instrument if exercised/converted

% of voting rights

-

-

-

-

-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise Price

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

-

-

-

-

-

-

-

 

Total A+B+C

Number of Voting rights

% of voting rights

10,038,352

5.03

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

 

Custodian

Day to Day IM

Total

BANK OF NEW YORK BRUSSELS (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

6,040

BANK OF NEW YORK MELLON

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

116,750

BNP PARIBAS SEC SVCS LONDON

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

45,902

BROWN BROS HARRIMN LTD LUX (C)

FMRC-FMR CO., INC

563

BROWN BROTHERS HARRIMAN AND CO

FMRC-FMR CO., INC

68,146

FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED

44,975

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

55,245

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

537,558

CIBC MELLON TRUST (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

13,333

CITIBANK NA, HONG KONG BR (S)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

16,382

JP MORGAN, BOURNEMOUTH (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

9,809

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

113,142

JPMORGAN CHASE BANK

FMRC-FMR CO., INC

4,142,658

FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED

151,087

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

34,638

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

54,815

MELLON BANK NA (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

259,991

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

72,600

NATIONAL BANK TRUST (C)

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

14,829

NOMURA TRUST AND BANKING (C)

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

553

NORTHERN TRUST CO (C)

FMRC-FMR CO., INC

207,323

FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED

2,598,333

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

36,157

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

272,510

STATE STREET BANK AND TR CO

FMRC-FMR CO., INC

312,875

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC

470,644

PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY

381,494

Grand Total

10,038,352

 

Proxy Voting

10

Name of the proxy holder

FMR LLC

11

Number of voting rights proxy holder will acquire

71.670

12

Date on which proxy holder will acquire voting rights

13th November 2015

 

13

Additional Information

14

Contact name:

Peter Speirs, Company Secretary

15

Contact telephone number:

020 7399 2772

 

- ENDS -

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUNRVRVAAAAAA
Date   Source Headline
9th May 20249:49 amRNSDirector/PDMR Shareholding
25th Apr 20242:28 pmRNSResult of AGM
25th Apr 20247:00 amRNSTrading Statement
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review
22nd Mar 20249:21 amRNSAnnual Financial Report and Notice of AGM
13th Mar 20249:42 amRNSDirector/PDMR Shareholding
7th Mar 20241:52 pmRNSDirector/PDMR Shareholding
1st Mar 202410:17 amRNSTotal Voting Rights
22nd Feb 20247:00 amRNSFinal Results
5th Feb 20248:46 amRNSNotice of Results
1st Feb 20246:22 pmRNSAgreement in Principle for US Opioid Settlement
1st Feb 202412:08 pmRNSTotal Voting Rights
2nd Jan 20243:24 pmRNSTotal Voting Rights
29th Dec 20237:00 amRNSCompany Secretary Change
1st Dec 20237:00 amRNSTotal Voting Rights
2nd Nov 20237:00 amRNSTrading Statement
2nd Oct 202310:13 amRNSBlock listing Interim Review
2nd Oct 202310:04 amRNSTotal Voting Rights
1st Sep 20237:00 amRNSTotal Voting Rights
31st Aug 20234:14 pmRNSDirector/PDMR Shareholding
11th Aug 20232:00 pmRNSDirector/PDMR Shareholding
10th Aug 20234:53 pmRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report
17th Jul 20239:11 amRNSNotice of Results
14th Jun 202310:03 amRNSHolding(s) in Company
8th Jun 202310:25 amRNSDirector/PDMR Shareholding
31st May 20233:20 pmRNSDirector/PDMR Shareholding
23rd May 20234:14 pmRNSHolding(s) in Company
17th May 20239:56 amRNSDirector/PDMR Shareholding
2nd May 202310:53 amRNSTotal Voting Rights
28th Apr 20233:25 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
24th Apr 20234:15 pmRNSDirector/PDMR Shareholding
12th Apr 20237:00 amRNSDirectorate Change
3rd Apr 20239:27 amRNSBlock listing Interim Review
3rd Apr 20239:19 amRNSTotal Voting Rights
16th Mar 202310:17 amRNSAnnual Financial Report and Notice of AGM
2nd Mar 20239:30 amRNSTotal Voting Rights
23rd Feb 20237:00 amRNSFinal Results
17th Feb 202310:20 amRNSHolding(s) in Company
7th Feb 20239:36 amRNSNotice of Results
1st Feb 202310:18 amRNSTotal Voting Rights
18th Jan 202310:16 amRNSDirector/PDMR Shareholding
18th Jan 20239:39 amRNSHolding(s) in Company
17th Jan 202311:58 amRNSHolding(s) in Company
10th Jan 20233:42 pmRNSAdditional Listing
10th Jan 20239:20 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.